Current Liabilities
Other accrued liabilities
Neurocrine Biosciences Other accrued liabilities decreased by 15.1% to $58.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.1%, from $47.70M to $58.70M. Over 5 years (FY 2020 to FY 2025), Other accrued liabilities shows an upward trend with a 31.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2016
Last reportedQ1 2026May 5, 2026
How to read this metric
Significant fluctuations may indicate changes in business model, such as shifts in deferred revenue recognition or changes in short-term regulatory obligations.
Detailed definition
This category includes miscellaneous short-term obligations that are not classified under accounts payable or accrued li...
Peer comparison
Commonly used as a catch-all for short-term liabilities; varies by industry and business model.
Metric ID:
current_liabilities_other_liabilities_currentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $22.00M | $20.00M | $20.00M | $17.60M | $20.00M | $18.10M | $20.70M | $18.40M | $21.20M | $18.70M | $35.90M | $36.70M | $40.00M | $37.00M | $46.10M | $47.70M | $56.80M | $53.70M | $69.10M | $58.70M |
| QoQ Change | — | -9.1% | +0.0% | -12.0% | +13.6% | -9.5% | +14.4% | -11.1% | +15.2% | -11.8% | +92.0% | +2.2% | +9.0% | -7.5% | +24.6% | +3.5% | +19.1% | -5.5% | +28.7% | -15.1% |
| YoY Change | — | — | — | — | -9.1% | -9.5% | +3.5% | +4.5% | +6.0% | +3.3% | +73.4% | +99.5% | +88.7% | +97.9% | +28.4% | +30.0% | +42.0% | +45.1% | +49.9% | +23.1% |
Range$17.60M – $69.10M
CAGR+23.0%
Avg YoY Growth+36.0%
Median YoY Growth+29.2%
Other accrued liabilities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's other accrued liabilities?
- Neurocrine Biosciences (NBIX) reported other accrued liabilities of $58.70M in Q1 2026.
- How has Neurocrine Biosciences's other accrued liabilities changed year-over-year?
- Neurocrine Biosciences's other accrued liabilities increased by 23.1% year-over-year, from $47.70M to $58.70M.
- What is the long-term trend for Neurocrine Biosciences's other accrued liabilities?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's other accrued liabilities has grown at a 31.2% compound annual growth rate (CAGR), from $17.80M to $69.10M.
- What does other accrued liabilities mean?
- Miscellaneous short-term debts or obligations not covered by other standard categories.